CagriSema FDA Approval Status 2026
For researchers and readers tracking the FDA review, the answer is no: as of October 22, 2026, CagriSema is not FDA approved. Novo Nordisk filed in December 2025 and expects a decision in Q4 2026. That window opened on October 1, so the answer may change before the year ends. No PDUFA date is public, and if CagriSema is approved, Novo plans a U.S. launch at the start of 2027. Below we set out the filing, the decision window, other regulators and the trial data. Each point is checked against FDA and Novo sources.
Status update, re-checked November 6, 2026: CagriSema is still not approved in the United States. In its nine-month report on November 4, 2026, Novo Nordisk said it is preparing a US launch of CagriSema in early 2027, subject to regulatory approval, and its investor presentation still gives Q4 2026 for the FDA decision; no public PDUFA date has been confirmed. The same report gave 21% weight loss at week 68 for the lower CagriSema dose (1.0 mg/1.0 mg) in REDEFINE 9. Mentions of Novo’s October 20 guidance elsewhere on this page reflect our earlier check.
Update History ▾
October 23, 2026: Relabelled the REDEFINE 4 figures of 23.0% and 25.5% as the efficacy estimand, as Novo’s February 23, 2026 release does, instead of "on treatment". Added REIMAGINE 4 to the head-to-head row (Novo, August 4, 2026: CagriSema 2.4/2.4 mg vs tirzepatide 15 mg in type 2 diabetes, 15.2% vs 15.8% weight loss at 68 weeks, non-inferior on weight but not on HbA1c) with its source, and stopped calling REDEFINE 4 the only head-to-head trial.
October 23, 2026: Replaced "muscle-sparing" with the REDEFINE-1 body composition figures presented at ECO 2026 (66.9% of weight lost was fat mass, 33.1% lean soft tissue; congress data), matching the CagriSema profile.
October 22, 2026: Re-checked status against FDA’s Novel Drug Approvals for 2026 list (updated October 20; 47 entries, no CagriSema), Drugs@FDA, the EMA list of centrally authorised medicines, EMA’s October 2026 list of medicines under evaluation, Health Canada’s Drug Product Database, ClinicalTrials.gov and Novo Nordisk’s releases of September 30 and October 20, 2026: unchanged, not approved, decision expected in Q4 2026, no public PDUFA date. Added the submission, other-regulator, launch and next-disclosure rows, a section on when an FDA decision is expected (with the 60-day filing step under 21 CFR 314.101), four FAQs and two dated 2026 updates. Corrected the filing basis to REDEFINE 1 and REDEFINE 2, the review-pathway line (Novo’s releases do not state the designation), the supportive secondary analysis, the completion-rate and REDEFINE 4 tolerability wording, the side-effect figures, the SELECT sentence and the brain-region comparison; removed an unsourced pipeline ranking; updated the REIMAGINE YOUNG registry title.
October 12, 2026: Re-checked status (FDA’s 2026 novel approvals list and Novo Nordisk releases): unchanged, not approved, no public PDUFA date. Corrected REDEFINE 3, which is the cardiovascular outcomes trial (no results yet), and REDEFINE 6, a completed trial in Chinese adults rather than an adolescent trial; added REDEFINE 2, the pediatric trials, Novo’s September 21 launch and readout guidance, the dual-chamber pen, zenagamtide’s Phase 3 status and petrelintide’s Phase 3 start; retitled the page without the month; replaced “COA-verified” on the retatrutide pen link with its published batch report; corrected petrelintide’s ZUPREME-1 tolerability (no vomiting at the maximally effective dose, not the highest dose; nausea 20% vs 6% and vomiting 3% vs 6% across all arms) and cited the Roche topline and the published paper.
October 11, 2026: Linked the CagriSema filing citation to the December 18, 2025 Novo Nordisk release, relabelled the Novo Nordisk pipeline and Lilly SURMOUNT-1 citations to match the linked pages, and added all listed references to the structured-data citations. Replaced the dead Lancet link for REDEFINE 1 with the trial’s 2025 New England Journal of Medicine paper (Garvey et al.) and corrected its comparator figures to Novo Nordisk’s reported values (semaglutide 16.1%, placebo 2.3%), noting that they assume full adherence.
October 7, 2026: Re-checked status. Unchanged — not approved; Novo restated the Q4 2026 U.S. decision timing on September 21, 2026, and no PDUFA date is public. Added the September 2026 REIMAGINE 5 (vs tirzepatide 5 mg, T2D) and REDEFINE 9 Phase 3 toplines, updated the retatrutide comparator stage, and refreshed freshness dates.
July 10, 2026: Replaced a dead Lilly weight-management URL with the exact SURMOUNT-1 primary-source release.
July 4, 2026: Re-verified U.S. status against Novo Nordisk IR and FDA sources. Unchanged — CagriSema remains under FDA review (NDA filed December 18, 2025), not approved, with no confirmed PDUFA date. Freshness dates refreshed.
June 21, 2026: US-market SEO/AEO refresh — title, meta, H1, and freshness signals aligned to “cagrisema FDA approval status 2026” queries; no regulatory status change.
June 15, 2026: Re-checked Novo Nordisk's current FDA-review language, aligned the page to the Q4 2026 decision window from Novo's Q1 2026 investor materials, and tightened the title/meta/FAQ answer surfaces for CagriSema and cagrilintide approval-status queries.
May 25, 2026: Re-checked Novo Nordisk's CagriSema NDA filing source and refreshed visible freshness, meta dateModified, and schema to May 25. Status unchanged: NDA filed, not FDA approved, no public PDUFA date.
May 23, 2026: Reframed the page around the REDEFINE-4 readout (failed non-inferiority vs tirzepatide), added the ECO 2026 body-composition discussion, and clarified that the Dec 18, 2025 NDA pre-dates REDEFINE-4 and is based on placebo-controlled REDEFINE-1.
May 17, 2026: Re-verified CagriSema status — NDA filed December 18, 2025 is still under FDA review; no advisory committee, PDUFA date, or other FDA action publicly disclosed; decision still expected in late 2026.
May 10, 2026: Softened title and meta certainty around FDA decision date (late 2026 expected, no confirmed PDUFA)
April 22, 2026: Tightened the direct-answer title, subtitle, verdict, and FAQ so the page answers the approval query before the click
Initial publication
Research summary
No. At the article’s October 22, 2026 status check, CagriSema was not approved for use in the United States. Novo Nordisk’s October 20 update said a U.S. decision was expected in Q4 2026; that is company guidance, not an FDA decision. FDA Novo Nordisk
- CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. ClinicalTrials.gov
- Clinical-trial findings do not change the approval status; check FDA records for any decision after the page’s review date.
Summary revised November 1, 2026. This editorial update does not constitute a new literature review.
Scope note: This approval tracker covers evidence and regulatory timing only. It does not cover pharmacy access, pricing, or research-supply listings. For broader context, use the approval trackers hub and the CagriSema profile.
Evidence and context
No. As of October 22, 2026, CagriSema is not approved by the FDA. FDA’s 2026 novel approvals list (updated October 20) and Drugs@FDA have no CagriSema entry. Novo Nordisk says the U.S. decision on the obesity filing it submitted on December 18, 2025 is expected in Q4 2026 (restated October 20, 2026), and no public PDUFA date has been confirmed. If approved, Novo expects a U.S. launch at the start of 2027. The current public evidence base still centers on placebo-controlled REDEFINE trials, the February 2026 REDEFINE-4 head-to-head readout versus tirzepatide, the February 2026 REIMAGINE-2 diabetes update, and the September 2026 REIMAGINE 5 and REDEFINE 9 toplines. Those data points matter for the review narrative, but they do not change the bottom line: CagriSema remains under FDA review, not approved.
- CagriSema is not approved as of October 22, 2026. Novo Nordisk filed the NDA on December 18, 2025. It rests on the REDEFINE 1 and REDEFINE 2 phase 3 trials, and Novo says it also submitted to Health Canada that month.
- Novo Nordisk's current guidance points to a Q4 2026 U.S. decision window (restated October 20, 2026); no public PDUFA date has been confirmed. Novo’s financial calendar lists its nine-month results for November 4, 2026.
- REDEFINE-1: 22.7% weight loss at 68 weeks vs 16.1% for semaglutide alone vs 2.3% placebo. REIMAGINE (Feb 2026, T2D): CagriSema showed superior HbA1c reduction (1.91 points) and 14.2% weight loss versus semaglutide.
- REDEFINE-4 (Feb 2026, vs tirzepatide 15 mg): 20.2% vs 23.6% at 84 weeks — primary endpoint (non-inferiority) not met. The obesity filing predates that readout and rests on the placebo-controlled REDEFINE 1 and REDEFINE 2 trials.
- September 2026 toplines: REIMAGINE 5 (T2D) — CagriSema 1.0/1.0 mg 12.4% vs tirzepatide 5 mg 9.1% weight loss at week 60 (superior), HbA1c −1.71% vs −1.67% (non-inferior). REDEFINE 9 — CagriSema 1.0/1.0 mg 21.0% vs 2.0% placebo at week 68.
- CagriSema remains an investigational once-weekly combination of cagrilintide 2.4 mg (amylin analog) and semaglutide 2.4 mg (GLP-1 agonist). At its September 21, 2026 Capital Markets Day, Novo said it expects a full U.S. launch at the start of 2027 if CagriSema is approved, with REDEFINE 11 and CagriSema HD readouts planned in H1 2027 and H1 2028.
| Item | Status (October 22, 2026) |
|---|---|
| FDA Approval | Not approved (no entry on FDA’s 2026 novel approvals list or in Drugs@FDA) |
| Submitted to FDA | Yes: NDA on December 18, 2025, based on REDEFINE 1 and REDEFINE 2 |
| NDA Submission Date | December 18, 2025 (in FDA’s terms, the filing date is 60 days after receipt) |
| Expected FDA Decision | Q4 2026 (restated by Novo on October 20, 2026; no public PDUFA date) |
| Review Designation | Not stated in Novo’s releases |
| Other Regulators | Health Canada: obesity submission in December 2025 (Novo, September 30, 2026); no product in the Drug Product Database. EMA: no CagriSema (cagrilintide/semaglutide) application on EMA’s October 2026 list of medicines under evaluation; no EU authorisation |
| U.S. Launch if Approved | Start of 2027 (Novo Capital Markets Day, September 21, 2026) |
| Next Company Disclosure | Nine-month 2026 results on November 4, 2026 (Novo financial calendar) |
| Clinical Stage | Pivotal Phase 3 complete; REDEFINE 3 cardiovascular outcomes trial ongoing (primary completion est. September 2027) |
| Best Placebo-Controlled WL | 22.7% at 68 weeks if all adhered; 20.4% vs 3.0% in the primary analysis (REDEFINE-1) |
| Head-to-Head vs Tirzepatide | 20.2% vs 23.6% at 84 wk vs tirzepatide 15 mg (REDEFINE-4); non-inferiority not met. 15.2% vs 15.8% at 68 wk vs tirzepatide 15 mg in T2D (REIMAGINE 4, 2.4/2.4 mg, reported Aug 4, 2026; efficacy estimand); non-inferior on weight, not on HbA1c. 12.4% vs 9.1% at 60 wk vs tirzepatide 5 mg in T2D (REIMAGINE 5, 1.0/1.0 mg); superior |
| Public PDUFA Date | Not disclosed |
| Developer | Novo Nordisk |
| Drug Type | Combination: cagrilintide + semaglutide |
| Dosing | Once weekly subcutaneous injection |
What Is CagriSema and How Does It Work?
CagriSema is Novo Nordisk’s investigational once-weekly subcutaneous injection that combines two active compounds in a single prefilled dual-chamber pen that keeps them in separate chambers: cagrilintide 2.4 mg, a long-acting amylin analog, and semaglutide 2.4 mg, a GLP-1 receptor agonist (the same active ingredient in Wegovy).
The rationale behind the combination is targeting two distinct hormonal pathways involved in appetite regulation and energy balance. Semaglutide activates GLP-1 receptors to reduce appetite and food intake — a well-established mechanism used in Wegovy and Ozempic. Cagrilintide mimics the hormone amylin, which is naturally co-secreted with insulin from pancreatic beta cells after meals. Amylin signaling promotes satiety, slows gastric emptying, and suppresses glucagon secretion. For a deeper look at this dual-pathway mechanism, see our CagriSema amylin and GLP-1 research profile.
By combining both pathways, CagriSema aims to produce greater weight loss than either component alone. The REDEFINE 1 trial data support this hypothesis — the combination outperformed semaglutide monotherapy by a clinically meaningful margin.
Once Weekly CagriSema: First-in-Class Combination Pharmacology
Novo’s filing release presents once weekly CagriSema as the first once weekly combination of a long acting amylin analogue with a GLP-1 receptor agonist. That first depends on approval: Novo’s October 20, 2026 release says CagriSema “has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management.” The underlying pharmacology centres on engaging two complementary satiety pathways simultaneously. Cagrilintide and semaglutide each act through distinct receptor systems — amylin receptors in the area postrema and GLP-1 receptors in the hypothalamus — creating a novel mechanism that produces additive effects on appetite suppression.
Novo’s chief executive called this amylin analogue combination approach a “first-in-class combination” when the application was filed. Public Novo Nordisk materials cited on this page continue to describe CagriSema as a fixed-dose combination of cagrilintide and semaglutide while the obesity filing remains under FDA review. The long-acting amylin analogue component (cagrilintide) has an extended half-life engineered through acylation technology, enabling once-weekly dosing rather than the multiple daily injections required by native amylin. In REDEFINE 1, which included cagrilintide-only and semaglutide-only arms, participants on CagriSema lost more weight than those on cagrilintide alone or semaglutide alone, supporting the rationale for the cagrilintide and semaglutide combination. The full mechanism is covered in the CagriSema research profile.
What Is CagriSema FDA Approval Status in 2026?
No — CagriSema is not FDA approved in 2026 as of October 22, 2026. Novo Nordisk filed a New Drug Application (NDA) with the FDA on December 18, 2025, seeking approval of CagriSema for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The filing was based on two phase 3 trials, REDEFINE 1 and REDEFINE 2, which together enrolled about 4,600 adults.
Novo says a U.S. decision on the obesity submission is expected in Q4 2026, most recently in its October 20, 2026 release. That release describes the December 2025 NDA as covering CagriSema for weight management and states that CagriSema is not approved for use in the United States. No exact PDUFA (Prescription Drug User Fee Act) target date has been publicly confirmed as of October 22, 2026. Track every pending decision on our obesity drug approval tracker for 2026.
The REDEFINE-4 readout in February 2026 missed the non-inferiority margin against tirzepatide 15 mg, but the NDA pre-dates that data and rests on the placebo-controlled REDEFINE 1 and REDEFINE 2 trials. The FDA evaluates total evidence of safety and efficacy versus placebo, so a head-to-head miss against a competitor does not, by itself, block approval. REIMAGINE (T2D, Feb 2026) also reported CagriSema outperforming semaglutide.
CagriSema has not received approval from any regulatory agency worldwide. Novo’s September 30, 2026 release says the obesity NDA went to the US FDA and Health Canada in December 2025. CagriSema does not appear on the European Medicines Agency’s (EMA) October 2026 list of new medicines under evaluation, and Novo has not announced an EU submission.
On October 22, 2026 we searched three regulator databases for cagrilintide and CagriSema. Health Canada’s Drug Product Database, the EMA list of centrally authorised medicines and Drugs@FDA returned no record. These databases list authorised products, and Drugs@FDA does not show pending applications, so an empty result means there is no approval record. It says nothing about how far the review has progressed.
When Is FDA Approval of CagriSema Expected?
Novo expects the FDA decision on CagriSema in Q4 2026, the quarter that runs from October 1 to December 31, 2026. It gave that window in its September 21, September 30 and October 20, 2026 releases. No PDUFA target date has been published, so there is no public CagriSema approval date yet. Novo’s releases do not say whether the application has a standard or priority review designation.
December 18, 2025: Novo Nordisk Files for FDA Approval
Novo’s release that day was titled “Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management.” The NDA covers CagriSema, a fixed-dose combination of cagrilintide and semaglutide, for adults with obesity, or overweight with at least one weight-related comorbid condition. It rests on two phase 3 trials: REDEFINE 1 in 3,417 adults without diabetes and REDEFINE 2 in 1,206 adults with type 2 diabetes. Novo’s September 30, 2026 release says the obesity application also went to Health Canada in December 2025.
From Filing to a Decision
- 60-day filing step: under 21 CFR 314.101(a)(1), FDA decides within 60 days of receiving an NDA whether the application may be filed, and under paragraph (a)(2) the filing date is 60 days after receipt. Novo submitted the NDA on December 18, 2025, so that point fell in mid-February 2026; “filed in December 2025” on this page follows Novo’s wording for the submission.
- Decision window: Q4 2026, restated by Novo on October 20, 2026. No public PDUFA date.
- Next company disclosure: Novo’s financial calendar lists its results for the first nine months of 2026 on November 4, 2026.
- CagriSema launch date: if FDA approves it, Novo said at its September 21, 2026 Capital Markets Day that it expects a full U.S. launch at the start of 2027. That is the closest thing to a CagriSema release date, and it depends on approval.
- Where an approval would appear: FDA’s Novel Drug Approvals for 2026 list and Drugs@FDA. We re-check both, along with Novo’s releases, each time this page is updated.
Other 2026 Watch Points Around the Review
Public 2026 reporting has covered more than the headline FDA timing. In February, Novo disclosed the REDEFINE-4 head-to-head result versus tirzepatide, and on May 6, 2026 Novo disclosed that it had ended a single-chamber co-formulation project; CagriSema is to be delivered in a dual-chamber pen instead (Fierce Biotech, May 6, 2026). Those updates matter for launch planning and investor expectations, but they do not change the regulatory bottom line on this page: CagriSema remains under FDA review, with no public PDUFA date posted.
The core evidence package remains the same: cagrilintide plus semaglutide, once weekly, supported by placebo-controlled REDEFINE data. Commercial presentation details may still evolve during review and launch planning, whereas the current FDA answer is still governed by the submitted clinical dossier and Novo’s public timing guidance.
ECO 2026 body composition (May 2026, Türkiye). A REDEFINE-1 sub-analysis presented at the European Congress on Obesity reported that 66.9% of the weight lost with CagriSema was fat mass and 33.1% was lean soft tissue — lean-mass preservation relative to total weight loss is increasingly a focus point across the GLP-1 class. See the Pharmaceutical Technology analyst comment.
EASD 2026 (September 30, 2026). Novo reported a 52-week functional MRI study in which CagriSema was associated with a 22.4% weight reduction versus placebo. The same release says a phase 3 efficacy and safety trial of high-dose CagriSema 2.4 mg/7.2 mg started in adults with obesity in 2026.
The Menopause Society (October 20, 2026). A post hoc analysis of the 2,309 women in the REDEFINE 1 clinical trial reported 25.0% average weight loss with CagriSema 2.4 mg / 2.4 mg versus 3.0% with placebo at week 68 (efficacy estimand). Novo calls such post hoc analyses hypothesis-generating, and the p-values were not adjusted for multiplicity. Neither update changes the regulatory status.
FDA Submission Details and Regulatory Pathway
Novo made the CagriSema FDA submission on December 18, 2025. Novo’s release that day says the NDA is based on two 68-week phase 3 trials from the REDEFINE clinical program: REDEFINE 1, the placebo- and active-controlled efficacy and safety trial in adults with obesity or overweight and no diabetes (22.7% weight loss at 68 weeks if all participants stayed on treatment), and REDEFINE 2, which tested CagriSema against placebo in adults with type 2 diabetes. Because the filing pre-dates the REDEFINE-4 February 2026 readout, the head-to-head miss against tirzepatide does not undercut the application’s evidentiary basis; the FDA review is driven by placebo-controlled efficacy and safety, not comparator positioning.
Novo’s releases do not say whether the FDA is reviewing the CagriSema application under a standard or a priority timeline. Any advisory committee meeting would be scheduled during the review period. If approval lands in the current Q4 2026 guidance window, launch-format questions may still sit alongside reimbursement and manufacturing decisions, but none of those commercial details change the current approval answer.
What Did the REDEFINE Trials Show?
The REDEFINE clinical program is Novo’s series of Phase 3 trials of CagriSema across different patient populations and treatment scenarios. Each clinical trial below tests the efficacy and safety of the combination against placebo or an approved drug. Some have not reported results yet. The headline results from the key trials:
REDEFINE 1: CagriSema 2.4 mg / 2.4 mg vs Placebo
REDEFINE 1 (obesity, primary trial): CagriSema demonstrated 22.7% mean body weight loss at 68 weeks, compared to 16.1% for semaglutide 2.4 mg alone and 2.3% for placebo. This was a head-to-head comparison with the active ingredient in Wegovy, and the 6.6 percentage-point difference was statistically significant. These figures assume all participants adhered to treatment; the primary analysis published in the New England Journal of Medicine in 2025, which counts all randomised participants, reported 20.4% versus 3.0% for placebo. That paper describes the trial arm as cagrilintide–semaglutide at 2.4 mg each; Novo labels it CagriSema 2.4 mg / 2.4 mg.
Other REDEFINE and REIMAGINE Trials
REDEFINE 2 (type 2 diabetes, NCT05394519): This phase 3 trial compared CagriSema with placebo in 1,206 adults with type 2 diabetes and overweight or obesity. Weight fell 13.7% with CagriSema versus 3.4% with placebo at 68 weeks, a statistically significant weight loss difference (treatment-policy estimand; Davies et al., New England Journal of Medicine, 2025). An HbA1c of 6.5% or less was reached by 73.5% of participants on CagriSema and 15.9% on placebo. With REDEFINE 1, it is one of the two pivotal trials behind the December 2025 U.S. submission.
REIMAGINE (type 2 diabetes, Feb 2026): In adults with type 2 diabetes, CagriSema outperformed semaglutide, with a superior HbA1c reduction (1.91 points) and 14.2% weight loss. Weight loss in people with type 2 diabetes is typically lower than in non-diabetic populations across all obesity drugs, so a T2D head-to-head win against the standard-of-care GLP-1 is a meaningful result for the combination. See Novo Nordisk's REIMAGINE disclosure.
REDEFINE 3 (cardiovascular outcomes, NCT05669755): A double-blind, placebo-controlled, event-driven trial in about 7,100 adults with established cardiovascular disease and a BMI of 25 or more, testing whether CagriSema 2.4/2.4 mg affects major adverse cardiovascular events. It is active, not recruiting, with primary completion estimated for September 2027. There are no results yet; the design and baseline paper was published in the American Heart Journal on October 6, 2026.
REDEFINE 4 (head-to-head vs tirzepatide, February 2026): In 809 participants with obesity and at least one weight-related comorbidity, CagriSema achieved 20.2% mean weight loss at 84 weeks versus 23.6% for tirzepatide 15 mg (treatment-regimen estimand; 23.0% and 25.5% on the efficacy estimand). CagriSema failed to meet the primary endpoint of non-inferiority to tirzepatide in this open-label trial. Novo said the most common adverse events with CagriSema were gastrointestinal and mostly mild to moderate. See our full REDEFINE 4 breakdown.
REIMAGINE 5 and REDEFINE 9 (September 2026): Novo reported both Phase 3 toplines on September 21, 2026, using the lower CagriSema 1.0 mg/1.0 mg dose. In REIMAGINE 5 (adults with type 2 diabetes), CagriSema showed 12.4% weight loss versus 9.1% for tirzepatide 5 mg at week 60 (superior), with a non-inferior HbA1c reduction (1.71% vs 1.67%). In REDEFINE 9 (overweight or obesity), CagriSema showed 21.0% weight loss versus 2.0% for placebo at week 68. Figures are based on the efficacy estimand. See the Novo release.
REDEFINE 6 (NCT05996848): A Phase 3 trial of CagriSema in 300 Chinese adults with overweight or obesity, compared with placebo and semaglutide; it was completed in February 2025 and no results have been posted. CagriSema’s pediatric clinical trials run much later: a trial in children and adolescents aged 8–18 (NCT07253285) has an estimated primary completion in March 2030, and REIMAGINE YOUNG (NCT07282613, ages 10–18 with type 2 diabetes) in September 2029.
Clinical Efficacy: Body Weight Reduction and Primary Endpoints
REDEFINE 1 had two coprimary end points at 68 weeks: the percent change in body weight and the share of participants losing 5% or more, each compared with placebo (Garvey et al., New England Journal of Medicine, 2025). Participants taking CagriSema achieved superior weight loss compared with the placebo group and the semaglutide monotherapy arm. The treatment effect size for body weight reduction was clinically meaningful, with consistent efficacy demonstrated across all pre-specified subgroups. Weight reduction of 22.7% represents substantial capacity to reduce excess body weight in adults living with either obesity or overweight with one or more comorbidities.
Placebo Group and Treatment Effect Size
In the placebo controlled REDEFINE 1 trial, the placebo group achieved only 2.3% weight reduction at 68 weeks, confirming that the treatment effect observed with once weekly CagriSema was attributable to the active compound rather than lifestyle intervention alone. All trial participants, including the placebo group, received counselling on reduced calorie diet and increased physical activity as part of standard background care. The average baseline body weight across the study population was consistent with other late stage trials in obesity, and the higher dose of semaglutide (2.4 mg) used in the active comparator arm set a high bar for demonstrating the weight loss potential of the combination. Novo’s December 18, 2025 release adds a supportive secondary analysis: 54% of participants with obesity at baseline who took CagriSema reached the threshold for non-obesity (BMI below 30) at week 68, compared with 11.1% in the placebo group. In the same release, 91.9% of participants taking CagriSema achieved at least 5% weight loss, compared with 31.5% on placebo (treatment-policy estimand). Weight also fell in the cagrilintide-only and semaglutide-only arms. Maintaining that weight reduction long term is the question for REDEFINE 11, an 80-week phase 3 trial with an 80-week extension.
Trial Participants and Completion Rates
The REDEFINE programme enrolled trial participants with either obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight related comorbid condition such as type 2 diabetes, hypertension, or dyslipidemia. Novo’s filing release credits the program with “high treatment completion rates”. Trial lengths differ: REDEFINE 1 and REDEFINE 2 ran for 68 weeks, REDEFINE 4 for 84 weeks, and REDEFINE 3 is still running. Discontinuation because of adverse events was 5.9% with CagriSema versus 3.5% with placebo in REDEFINE 1, and 8.4% versus 3% in REDEFINE 2. Novo describes the tolerability profile as consistent with the drug’s underlying pharmacology. The most common adverse events were gastrointestinal—nausea, diarrhea, and vomiting—and these common adverse events occurred primarily during the dose-escalation phase. Patient relevant outcomes, including quality-of-life measures and physical function, were assessed as secondary endpoints.
CagriSema vs Incretin Agonists
CagriSema occupies a mechanistically distinct position from the incretin-based agonists dominating the obesity pipeline. Tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/GCGR triple agonist) both operate within the incretin receptor superfamily, stacking overlapping downstream signaling cascades — GLP-1R and GIPR share cAMP-dependent pathways, and GCGR adds energy expenditure via hepatic signaling. Remy Research supplies a research-grade retatrutide pen with a published Janoshik batch report, for laboratory use in Dubai. CagriSema takes a fundamentally different approach: it pairs semaglutide’s GLP-1 receptor activation with cagrilintide’s engagement of the amylin receptor system, targeting two non-overlapping satiety pathways. For research on pairing cagrilintide with retatrutide instead of semaglutide, see retatrutide and cagrilintide research.
The receptor pharmacology distinction is significant. Incretin-based combinations target receptors from the same family — GLP-1R, GIPR, and GCGR are all class B1 G-protein-coupled receptors that share structural homology and downstream signaling elements. CagriSema’s amylin component acts through a different receptor system: the calcitonin receptor (CALCR) complexed with receptor activity-modifying proteins (RAMPs), which together form the amylin receptor subtypes (Hay et al., 2015). Amylin acts principally in the circumventricular organs, including the area postrema, a site outside the blood-brain barrier, while GLP-1 acts on hypothalamic appetite circuits and brainstem GLP-1 receptors. The receptor systems do not overlap, although both components act in the brainstem, where the area postrema sits. What CagriSema adds is a second receptor system that incretin-only combinations do not use.
In clinical terms, the REDEFINE 4 head-to-head trial showed tirzepatide outperforming CagriSema on the primary weight-loss endpoint (23.6% vs 20.2% at 84 weeks). However, the non-overlapping pathway rationale remains valuable for research — specific metabolic subpopulations where incretin resistance or amylin-pathway deficiency limits GLP-1/GIP efficacy may respond differently to amylin-based combination strategies. The mechanistic breakdown above covers the full amylin and GLP-1 research profile for CagriSema.
| Feature | CagriSema | Tirzepatide | Retatrutide |
|---|---|---|---|
| Pathway Type | Non-overlapping (Amylin + GLP-1) | Overlapping incretin (GLP-1 + GIP) | Overlapping incretin (GLP-1 + GIP + GCGR) |
| Receptor Targets | CALCR/RAMP + GLP-1R | GLP-1R + GIPR | GLP-1R + GIPR + GCGR |
| Key Brain Regions | Area postrema and other brainstem sites + hypothalamus | Hypothalamus + brainstem | Hypothalamus + brainstem + liver |
| Developer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Clinical Stage | NDA filed (Dec 18, 2025); current guidance points to Q4 2026 | FDA approved | Phase 3; US filing planned by Q1 2027 |
CagriSema in the Amylin Landscape
CagriSema is not the only compound advancing the amylin thesis. Petrelintide, a standalone long-acting amylin analog developed by Roche and Zealand Pharma, reported Phase 2 results (ZUPREME-1) in March 2026 with a compelling profile: up to 10.7% weight loss at 42 weeks and a “placebo-like” GI tolerability profile. At the maximally effective dose there were no vomiting cases and no discontinuations for gastrointestinal adverse events (Roche topline, March 5, 2026); across all petrelintide arms, the published paper reports nausea in 20% of participants versus 6% on placebo and vomiting in 3% versus 6%. Zealand announced the start of the Phase 3 ZUPREME program, run with Roche, on September 22, 2026, and ZUPREME-2 reported up to 9.2% versus 2.0% weight loss at week 28 in people with type 2 diabetes on October 7, 2026. For a full compound breakdown, see our petrelintide research profile.
On headline weight-loss numbers, CagriSema leads significantly: 22.7% versus petrelintide’s 10.7%. But direct comparison requires caution — these figures come from different trial designs, different patient populations, and different durations (REDEFINE 1 at 68 weeks vs ZUPREME-1 at 42 weeks). CagriSema’s higher efficacy is expected given that it combines two active mechanisms (amylin + GLP-1), while petrelintide targets only the amylin pathway as a monotherapy. The more relevant question is not which produces more weight loss in isolation, but how each positions within the broader treatment landscape.
Petrelintide’s exceptional tolerability raises a strategic question for the amylin field: could a standalone amylin analog with minimal GI burden serve as an add-on therapy to existing GLP-1 regimens? GI side effects are the primary reason patients discontinue GLP-1-based treatments, and a drug that delivers meaningful weight loss without compounding the side-effect load becomes an attractive combination partner. Petrelintide could theoretically be layered on top of semaglutide, tirzepatide, or retatrutide — providing amylin-pathway benefit that CagriSema bundles in a fixed dose but that standalone amylin analogs could deliver more flexibly. For a detailed head-to-head analysis, see our petrelintide vs CagriSema comparison.
| Feature | CagriSema | Petrelintide |
|---|---|---|
| Mechanism | Amylin + GLP-1 (combination) | Amylin monotherapy |
| Developer | Novo Nordisk | Roche / Zealand Pharma |
| Weight Loss | 22.7% at 68 weeks | 10.7% at 42 weeks |
| GI Tolerability | Standard GLP-1 GI profile | Placebo-like apart from nausea (vomiting 3% vs 6%; none at the maximally effective dose) |
| Clinical Stage | NDA filed (Dec 2025) | Phase 3 (ZUPREME program, started September 2026) |
| Combination Potential | Already includes semaglutide | Can add to existing GLP-1 therapies |
| Feature | CagriSema | Wegovy | Zepbound |
|---|---|---|---|
| Mechanism | Amylin + GLP-1 | GLP-1 | GLP-1 + GIP |
| Weight Loss | 22.7% at 68 wk (REDEFINE 1) | 16.1% at 68 wk (REDEFINE 1 comparator) | 22.5% at 72 wk (SURMOUNT-1) |
| Phase | NDA filed (Phase 3 complete) | FDA approved | FDA approved |
| Status (October 2026) | Under FDA review | Commercially available | Commercially available |
| Dosing | Once weekly SC injection | Once weekly SC injection | Once weekly SC injection |
| Developer | Novo Nordisk | Novo Nordisk | Eli Lilly |
What Are the Side Effects of CagriSema?
The side-effect profile of CagriSema in the REDEFINE trials was broadly consistent with the known effects of GLP-1 receptor agonists. The most commonly reported adverse events were gastrointestinal: nausea, vomiting, and diarrhea. These GI side effects were generally mild to moderate and most common during the dose-escalation phase.
Gastrointestinal adverse events were more common with CagriSema compared with placebo. In REDEFINE 1 they affected 79.6% of participants on CagriSema and 39.9% on placebo, and they were mainly transient and mild to moderate (Garvey et al., New England Journal of Medicine, 2025). The overall rate was slightly higher with CagriSema than with semaglutide 2.4 mg alone (73.8%). Novo’s December 18, 2025 release lists nausea in 55% versus 12.6%, constipation in 30.7% versus 11.6% and vomiting in 26.1% versus 4.1%. In REDEFINE 2, 72.5% of participants on CagriSema and 34.4% on placebo reported gastrointestinal adverse events, most of them transient and mild or moderate (Davies et al., 2025). Cagrilintide slows gastric emptying through amylin signaling, on top of semaglutide’s GLP-1-mediated effects on gastric motility.
Discontinuation rates are listed under trial completion above. Novo says the safety data from REDEFINE 1 and REDEFINE 2 were comparable with the GLP-1 receptor agonist class. The full safety dataset from the REDEFINE program is part of the NDA currently under FDA review. For context on where CagriSema fits among other investigational compounds, see our obesity drug approval tracker.
What Happens Next?
Four developments define the near-term trajectory for CagriSema:
1. FDA review decision (Q4 2026 guidance). The NDA filed December 18, 2025 is under review. Novo Nordisk's current guidance points to a Q4 2026 U.S. decision window, restated on October 20, 2026, and no exact PDUFA date has been publicly confirmed. Novo reports its nine-month 2026 results on November 4, 2026. Any advisory committee meetings or FDA information requests would be announced publicly.
2. Launch timing. At its September 21, 2026 Capital Markets Day, Novo said it expects a full U.S. launch at the start of 2027 if CagriSema is approved. CagriSema is to be delivered in a dual-chamber pen after Novo ended its single-chamber co-formulation project in May 2026. Both remain secondary to the FDA review outcome and any eventual label details.
3. Next CagriSema readouts. Novo plans the REDEFINE 11 readout in H1 2027 and the higher-dose CagriSema HD readout in H1 2028. The REDEFINE 3 cardiovascular outcomes trial has an estimated primary completion in September 2027. Pediatric data are years away: NCT07253285 (ages 8–18) is estimated to complete in March 2030 and REIMAGINE YOUNG (NCT07282613) in September 2029.
4. Competitive landscape. CagriSema enters a market where tirzepatide (Zepbound) is already approved with comparable weight-loss figures (22.5% in SURMOUNT-1) and outperformed CagriSema in REDEFINE-4, the top-dose head-to-head trial in obesity (23.6% vs 20.2% at 84 weeks). Competitive positioning depends on the amylin–GLP-1 mechanism, the ECO 2026 body composition data, and whether the FDA views the current package as differentiated enough for approval. Retatrutide (Eli Lilly’s triple-agonist, Phase 3; Lilly plans to submit retatrutide for US approval in Q1 2027) and survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist, Phase 3) are also advancing. See our retatrutide vs tirzepatide vs CagriSema comparison for a full breakdown.
Novo Nordisk’s Obesity Pipeline and Market Outlook
Novo Nordisk’s obesity pipeline extends well beyond CagriSema. The company’s portfolio includes semaglutide (Wegovy), which already commands significant market share in the GLP-1 obesity category, and zenagamtide (amycretin), a unimolecular GLP-1/amylin agonist now in Phase 3: the AMAZE obesity program began in February 2026, the oral tablet trial AMAZE 9 started in August 2026, and type 2 diabetes is being tested in AMBITION 7. If approved, CagriSema would expand treatment options for healthcare professionals managing patients with obesity and provide patients with an additional treatment option supported by well-powered Phase 3 data. Within the CagriSema program, REDEFINE 11 is under way and a phase 3 trial of high-dose CagriSema 2.4 mg/7.2 mg started in adults with obesity in 2026.
Addressing Unmet Medical Needs in Obesity Care
The approval of CagriSema would address unmet medical needs in obesity care by providing a novel mechanism distinct from existing GLP-1-only and GLP-1/GIP dual agonist therapies. Healthcare professionals increasingly recognise that treatment options for obesity must account for metabolic disease, obesity related complications, and the broader cardiometabolic burden associated with obesity. CagriSema’s dual pathway approach could provide patients with a holistic treatment strategy that targets both appetite regulation and metabolic dysfunction. Event driven cardiovascular outcomes trials have set a precedent for the class. In SELECT, which enrolled people with overweight or obesity and established cardiovascular disease but no diabetes, a major adverse cardiovascular event occurred in 6.5% of patients on semaglutide 2.4 mg and 8.0% on placebo (hazard ratio 0.80; Lincoff et al., New England Journal of Medicine, 2023). The trial measured the effect of the drug and was not designed to show how much of that benefit came from weight loss. Non obesity indications, including type 2 diabetes management and potential benefits for metabolic disease comorbidities, represent additional opportunities to expand treatment options and grow market share. As the higher dose formulations of existing therapies face competition, the cagrilintide and semaglutide combination aims to offer unmet medical needs coverage that single-agent therapies cannot match.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635–647. nejm.org
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. December 18, 2025. novonordisk.com
- GlobeNewswire. Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity — primary endpoint was not achieved. February 23, 2026. globenewswire.com
- Novo Nordisk. CagriSema demonstrated superior HbA1c reduction (1.91 points) and 14.2% weight loss vs semaglutide in adults with type 2 diabetes (REIMAGINE programme). February 2026. novonordisk.com
- Pharmaceutical Technology. ECO 2026 — REDEFINE-1 CagriSema body composition analysis (Türkiye). May 2026. pharmaceutical-technology.com
- Novo Nordisk. R&D pipeline. novonordisk.com
- ClinicalTrials.gov. REDEFINE 1: A Research Study to Look at How Well CagriSema Works in People Living With Overweight or Obesity (NCT05567796). clinicaltrials.gov
- Eli Lilly. Lilly’s SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight. June 4, 2022. lilly.com
- Novo Nordisk. Novo’s CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial (REIMAGINE 5 and REDEFINE 9 toplines; decision expected Q4 2026). September 21, 2026. globenewswire.com
- Eli Lilly. Lilly’s triple agonist retatrutide successful in two additional Phase 3 trials; BLA submission planned Q1 2027. July 23, 2026. lilly.com
- Davies MJ, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648–659. doi:10.1056/NEJMoa2502082. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. REDEFINE 2: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (NCT05394519). Checked October 22, 2026. clinicaltrials.gov
- ClinicalTrials.gov. REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (NCT05669755). Active, not recruiting; primary completion estimated September 2027. Checked October 22, 2026. clinicaltrials.gov
- Cavender MA, et al. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J. Published online October 6, 2026. doi:10.1016/j.ahj.2026.107626. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. REDEFINE 6: A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (NCT05996848). Completed February 2025; 300 adults. Checked October 22, 2026. clinicaltrials.gov
- ClinicalTrials.gov. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (NCT07253285). Recruiting; ages 8–18; primary completion estimated March 2030. Checked October 22, 2026. clinicaltrials.gov
- ClinicalTrials.gov. REIMAGINE YOUNG: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (NCT07282613). Recruiting; ages 10–18; primary completion estimated September 2029. Checked October 22, 2026. clinicaltrials.gov
- Novo Nordisk. Capital Markets Day 2026: US Operations presentation (CagriSema full launch expected at the start of 2027 pending decision; REDEFINE 11 and CagriSema HD readouts planned in H1 2027 and H1 2028). September 21, 2026. novonordisk.com
- Fierce Biotech. Novo CEO insists “no change in plan” for CagriSema launch after single-chamber device ditched (CagriSema to be delivered in a dual-chamber system). May 6, 2026. fiercebiotech.com
- Gulisano W, et al. Ease of use, ease of learning, and convenience of the CagriSema dual-chamber pen: results from a usability study. J Diabetes Sci Technol. Published online June 28, 2026. doi:10.1177/19322968261461530. pubmed.ncbi.nlm.nih.gov
- Zealand Pharma. Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity. September 22, 2026. globenewswire.com
- Zealand Pharma. Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes. October 7, 2026. globenewswire.com
- Roche. Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity (ZUPREME-1 topline). March 5, 2026. roche.com
- Garvey WT, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. Published online September 29, 2026. doi:10.1016/S2213-8587(26)00213-5. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight (NCT07339423). Recruiting; started February 24, 2026. Checked October 22, 2026. clinicaltrials.gov
- ClinicalTrials.gov. AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight (NCT07720271). Recruiting; started August 31, 2026. Checked October 22, 2026. clinicaltrials.gov
- U.S. Food and Drug Administration. Novel Drug Approvals for 2026 (47 entries as of October 22, 2026, the latest Hibsago on October 20, 2026; Foundayo, April 1, 2026; no CagriSema or retatrutide entry). fda.gov
- Novo Nordisk. Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting (a decision is expected in Q4 2026; CagriSema is not approved for use in the United States). October 20, 2026. novonordisk.com
- Novo Nordisk. Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026 (obesity NDA submitted to the US FDA and Health Canada in December 2025). September 30, 2026. globenewswire.com
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563. pubmed.ncbi.nlm.nih.gov
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564–600. doi:10.1124/pr.115.010629. pubmed.ncbi.nlm.nih.gov
- Electronic Code of Federal Regulations. 21 CFR 314.101: Filing an NDA and receiving an ANDA (paragraph (a)(1), 60-day filing determination; paragraph (a)(2), filing date 60 days after receipt). Checked October 22, 2026. ecfr.gov
- Novo Nordisk. Financial calendar (financial results for the first nine months of 2026 on November 4, 2026). Checked October 22, 2026. novonordisk.com
- European Medicines Agency. Medicines evaluated through the centralised procedure (no cagrilintide or CagriSema entry). Checked October 22, 2026. ema.europa.eu
- European Medicines Agency. Applications for new human medicines under evaluation by the CHMP: October 2026 (data extracted October 5, 2026; no cagrilintide or CagriSema entry). Published October 9, 2026. Checked October 22, 2026. ema.europa.eu
- Health Canada. Drug Product Database (no cagrilintide or CagriSema product). Checked October 22, 2026. health-products.canada.ca
- U.S. Food and Drug Administration. Drugs@FDA (no cagrilintide application record; pending applications are not listed). Checked October 22, 2026. accessdata.fda.gov
- Novo Nordisk. Financial report for the period 1 January 2026 to 30 June 2026 (REIMAGINE 4: CagriSema 2.4/2.4 mg vs tirzepatide 15 mg for 68 weeks in type 2 diabetes; weight loss 15.2% vs 15.8%, non-inferior; HbA1c reduction 1.9 vs 2.2 percentage points, non-inferiority not met). August 4, 2026. sec.gov